In recent years, it has been shown that many of the pervasive genetic defects in cancer occur in chromatin modifiers. Herein, we analyzed the distribution and mutual relationships of genetic aberrations in relevant chromatin modifiers in tens of thousands of publicly available cancer datasets. We observed that in general, they are mutually exclusive, and their prevalence is higher in some types of cancers compared to others. Moreover, we observed a strong association between aberrations in selected chromatin modifiers and tumor mutational burden, leading to an improved response to checkpoint immunotherapy. All in all, this study uncovered interesting relationships between chromatin factors and features of cancer, which warrant follow up functional and clinical studies.
BACKGROUND
Cancer denotes a multifaceted group of diseases, generally characterized by cell regulation failure, which results in abnormal and uncontrolled cell growth. These properties equip the cells with the potential to divide in an uncontrolled manner, hide from the immune system, and over time, invade and spread into neighboring tissues and organs of the body [1] . Cancer is thought to be driven by the accumulation of genetic defects such as mutations, deletions, amplifications and translocations in so-called oncogenes and tumor-suppressor genes [2] . Therefore, historically, most of the endeavors undertaken in cancer biology have been focused on genetic aberrations in genes with prominent roles in DNA repair, cell proliferation, and cell signaling. However, in the past years, with the broad application of NGS sequencing technologies for comprehensive cancer profiling it has been shown that many of the pervasive genetic defects in cancer occur in epigenetic (chromatin) regulators [3] . Such mutations in chromatin writers, readers, erasers, remodelers and even the histone proteins themselves, can lead to global alterations in the chromatin of cells, which in turn can steer the cells to altered epigenetic states and expression programs that contribute to tumorigenesis [4] [5] [6] . This indicates that genetic alterations of chromatin regulators provide the cancer cell with a very efficient means to rewire its transcriptional programs and adapt quickly to microenvironmental or therapeutic pressures [7] . In addition, simply because of the sheer ubiquity of mutations in epigenetic modifiers in most types of cancer, they are increasingly regarded as novel targets for cancer treatment. Hence, obtaining a greater understanding and deeper insights into the frequency, distribution, mutual relationships and features of these regulators in cancer can significantly aid our understanding of cancer biology. In this study, we sought to analyze the distribution, mutual relationships and features of selected 57 chromatin modifiers in tens of thousands of available genetic maps of different types of cancers.
RESULTS

The presence of genomic alterations in chromatin modifiers is pervasive in cancer
We tested the prevalence and distribution of genomic alterations in 57 genes selected from literature [8, 9] coding for chromatin modifiers in 158 non-redundant studies encompassing 31254 tumor samples from the TCGA study and others, as well as 28 genes in 10945 tumor samples from the MSK-IMPACT study [10] (Additional File 1, Suppl. Figures 1 and 2 ) deposited in the cBioportal platform [11, 12] . Our preliminary analysis revealed that chromatin remodelers were the most frequently altered epigenetic category of regulators, followed by histonemodifying, and DNA modifying enzymes Figure 3C) . As a proof of principle, we have detected readily known aberrations such as enrichment of PBRM1 in renal cancer, and enrichment of ATRX with IDH1 in gliomas [13] (Figure 1 ). Particular types of cancers (e.g lung cancer, bladder cancer, diffuse glioma, uterine cancer, skin cancer) had a higher incidence of genomically altered chromatin modifiers in contrast to others (e.g rhabdoid cancer, thyroid cancer, peripheral nervous system cancers, Wilms tumors) ( Figure 1 ; Additional File 1, Suppl. Figure 2 ).
Genomic alterations in chromatin modifiers are mutually exclusive in cancer
To get a better insight of the mutual relationships between genomically altered chromatin modifiers, we wanted to study their Genomic alterations in selected chromatin modifiers are associated with higher TMB and an improved response to checkpoint immunotherapy Next, we sought to investigate the relationships between genomically altered chromatin modifiers and other molecular and clinical features, such as tumor mutational burden (TMB), and patient survival. Interestingly, cancers with high mutation rates (Additional File 1, Suppl. Figure 17A and B) , such as endometrial cancer, colorectal cancer, skin cancer, glioma, lung cancer, and bladder cancer were the types of cancers with a high prevalence of genomically altered chromatin modifiers (Figure 1;  Additional File 1, Suppl. Figure 2) . To delve deeper into this relationship, we analyzed the TMB levels per chromatin modifier in comparison to canonical TMB markers such as the presence of DNA mismatch repair (MMR) mutations (MLH1, MSH2, MSH6, PMS2) and POLE or POLD1 mutations. These results demonstrated higher TMB levels in cancers harboring alterations of certain chromatin modifiers (e.g. DNMT3B, SMARCD1 and other) in comparison to cancers harboring mutations in canonical oncogenes/tumor-suppressors, the MMR machinery or POLE/POLD1 ( Figure 3A ; Additional File 1, Suppl. Figure 18A) . Next, we wanted to ascertain if the co-occurrence of mutations in the MMR machinery or POLE/POLD1 together with alterations in chromatin modifiers would have an effect on TMB. Indeed, the co-occurrence of mutations in the MMR machinery or POLE/POLD1 together with alterations in selected (high TMB CMs, medium TMB CMs, and low TMB CMs) chromatin modifiers had a cumulative effect, and the highest level of TMB ( Figure 3B;  P<0.0001, Dunn's test) . To further refine this observation, we selected datasets harboring only MMR or POLE/POLD1 mutations respectively, mutations only in high TMB CMs or combination of both. These analyses validated our previous observation that the presence of mutations in both chromatin modifiers and the MMR or POLE/POLD1 machinery leads to a cumulative effect and the highest level of TMB ( Figure 3C and D, P<0.0001, Dunn's test) . Since high TMB levels have been associated with better response to immunotherapy with checkpoint inhibitors [14, 15] , to assess the clinical relevance of our observations, we reanalyzed the data of non-small lung cell carcinoma patients treated with checkpoint inhibitors from the MSKCC cohort [16] . Patients harboring mutations in chromatin modifiers, which are associated with high TMB (Additional File 1, Suppl. Figure 18A ) had a better durable effect compared to controls of all MSK genes or oncogenes/tumor-suppressors (P value, 0.028, and 0.029, respectively, Fisher's exact test) ( Figure 3E; Additional File 1, Suppl. Figure 18B) .
The presence of genomic alterations in chromatin modifiers have an effect on survival
Finally, we wanted to evaluate the effect on the survival of patients harboring alterations in a chromatin modifier. We performed logistic regression analysis on TCGA data, and noticed that patients with mutations in the genes SMARCD1, DNMT3L, TET3, and KMT2A and amplifications in EP300, KMT2B, KDM5C, DNMT3L, HDAC4, SMARCA4, ARID2 and HDAC9 led to a worse survival prognosis, while mutations in NSD1, CHD6, ARID1A, IDH1, IDH2 and amplifications in HDAC2, IDH1 had a better survival prognosis (Additional File 1, Suppl. Figure 19 ; Additional File 5).
DISCUSSION
In this report, we sought to comprehensively study the features of thousands of cancer samples harboring genomic alterations in selected chromatin modifiers. Our study shows in detail that many of the pervasive genetic defects in cancer occur in the epigenetic machinery. Furthermore, the difference in the ubiquity of altered chromatin modifiers in some cancer types compared to others underlines the importance of epigenetic dysregulation for cancer formation and cancer progression. This means that some cancers might be more dependent on genetically induced epigenetic changes than others. From a mechanistic point of view, we discovered that in general, the presence of genomic alteration in one chromatin modifier is mutually exclusive with a genomic alteration in another. This observation illustrates that the underlying epigenetic landscape of cancer is highly selective and non-random, and alterations in too many essential chromatin factors might be unfavorable for the process of tumorigenesis. On the other hand, there are conspicuous cases where genetic aberrations in two or more chromatin modifiers co-occur together -which might point out to interesting interplays between major epigenetic networks (e.g. co-occurring amplifications of DNMT1, SMARCA4, and BRD4 or co-occurring deletions in HDAC2 and ARID1B). Approaches based on targeted dysregulation (genomic alteration) of one or multiple chromatin regulators coupled with functional analyses of the epigenome, might serve as an interesting basis for follow up studies, and novel targeted therapies. High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors (PD-1 and PD-L1 blockade); Alterations in the DNA mismatch repair pathway and DNA polymerase ε have been used as a proxy for high TMB. Herein we showed that cancers harboring alteration in selected (not all) chromatin modifiers exhibit high TMB independently or MMR or POLE/POLD1. In addition to that, we discovered that mutations in selected chromatin modifiers are associated with a more durable effect with checkpoint immunotherapy in patients with lung cancer. This find is quite relevant in the current developments of checkpoint immunotherapy and warrants further retrospective and prospective clinical studies. Finally, alterations in selected chromatin modifiers led to a worse/better patient prognosis, which in turn might encourage their development as prognostic markers in the future. All things considered, this study unveiled potential relationships between chromatin factors and cancer features and set the stage for additional follow up functional and clinical studies.
METHODS
All genomic datasets reported in this study were downloaded from the cBioportal platform, http://www.cbioportal.org/, and statistically analyzed, and visualized in Microsoft Excel, Google Sheets, StatsDirect and Prism or other tools integrated within the cBioportal platform 11, 12 . Supplementary Figures 2 and 3 were carried out on cancer datasets with >100 samples. The public cBioPortal is currently using hg19/GRCh37 version of the human reference genome. The main focus was put into MSK-IMPACT and TCGA datasets 10, 17 https://www.cancer.gov/tcga. 
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